In 2018, the NIA-AA published three biomarkers for AD, i.e., Aβ accumulation-related biomarkers (A), Tau accumulation-related biomarkers (T), and neurodegeneration (N)-related biomarkers or other biomarkers of specific pathological processes, referred to as ATN. The gene discussed is MAPT; the disease is oculocutaneous albinism type 1.